RNA-seq data of BRAF wild-type and BRAF mutant tumor cells treated with the ERK inhibitor GDC-0994 - - GEO DataSets

Summary

Format

Summary
Summary (text)
Unique Identifier List

Send to:

Choose Destination

File
Clipboard
Collections

Links from BioProject

RNA-seq data of BRAF wild-type and BRAF mutant tumor cells treated with the ERK inhibitor GDC-0994

(Submitter supplied) BRAF or RAS mutation-induced aberrant activation of the mitogen-activated protein kinase (MAPK) pathway is frequently observed in human cancers. As the key downstream node of MAPK pathway, ERK1/2 is as an important therapeutic target. GDC-0994 (ravoxertinib), an orally bioavailable, highly selective small-molecule inhibitor of ERK1/2, showed acceptable safety and pharmacodynamic profile in a recent phase I clinical trial. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL24676
12 Samples

Download data: TXT

Series

Accession:: GSE264049

ID:: 200264049

Analyze with GEO2R

Supplemental Content

GEO DataSets

Functional Genomics Studies

Result Filters

Send to:

Links from BioProject

Supplemental Content

Related information

Important Links

Recent activity